GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide | CalcMyPeptide

1. What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone. When food enters the digestive system, the gut releases GLP-1, which signals the pancreas to produce insulin, suppresses glucagon secretion, slows gastric emptying, and communicates satiety to the brain.

Synthetic GLP-1 agonists amplify these effects far beyond what natural GLP-1 can achieve. They have been FDA-approved for type 2 diabetes management since 2005 (exenatide/Byetta) and for chronic weight management since 2014 (liraglutide/Saxenda), with dramatically more effective agents introduced since 2021.

GLP-1 Mono

Semaglutide (Ozempic, Wegovy)

Single incretin — targets GLP-1 receptor only

GIP/GLP-1 Dual

Tirzepatide (Mounjaro, Zepbound)

Dual incretin — activates both GIP and GLP-1 receptors

GIP/GLP-1/Glucagon Triple

Retatrutide (Phase III)

Triple agonist — adds glucagon receptor for increased energy expenditure

2. Why Dose Escalation Is Required

GLP-1 agonists require gradual dose escalation over 4-20 weeks to minimize gastrointestinal side effects — primarily nausea, vomiting, diarrhea, and constipation. Starting at the full therapeutic dose often causes intolerable GI distress and leads to treatment discontinuation.

The reason: GLP-1 receptor activation significantly slows gastric emptying (the rate food leaves the stomach). At low doses, the body gradually adapts to this slower transit time. Jumping directly to a high dose overwhelms the GI system before adaptation can occur.

Key principle: Each dose step is maintained for 4 weeks minimum before escalating. Some clinicians extend to 8 weeks if side effects persist. Escalation should not proceed until current-dose side effects are manageable.

Dose escalation also allows clinicians to find the minimum effective dose for each patient. Not everyone needs the maximum dose — many patients achieve satisfactory results at intermediate dose steps, with fewer side effects and lower cost.

3. Semaglutide: Wegovy & Ozempic Schedules

Semaglutide has a ~7-day half-life, making once-weekly injection convenient and effective. Two FDA-approved formulations exist with different indication-specific dose targets:

Wegovy (Weight Management)

Weeks 1-4 → 0.25 mg

Weeks 5-8 → 0.5 mg

Weeks 9-12 → 1.0 mg

Weeks 13-16 → 1.7 mg

Week 17+ → 2.4 mg (maintenance)

Source: FDA Label (Wegovy)

Ozempic (Type 2 Diabetes)

Weeks 1-4 → 0.25 mg

Weeks 5-8 → 0.5 mg

Week 9+ → 1.0 mg (up to 2.0 mg)

Source: FDA Label (Ozempic)

The weight management dose target (2.4 mg) is significantly higher than the diabetes dose (1.0-2.0 mg), reflecting the STEP clinical trial findings that higher doses produce greater weight loss. Average weight loss in the STEP 1 trial was 14.9% at the 2.4 mg dose over 68 weeks.

4. Tirzepatide: Mounjaro & Zepbound Schedules

Tirzepatide is a dual GIP/GLP-1 receptor agonist with a ~5-day half-life. By activating both incretin receptors, it achieves greater glycemic control and weight loss than GLP-1-only agents in head-to-head trials.

Mounjaro / Zepbound Schedule

Weeks 1-4 → 2.5 mg

Weeks 5-8 → 5.0 mg

Weeks 9-12 → 7.5 mg (optional step)

Weeks 13-16 → 10.0 mg

Weeks 17-20 → 12.5 mg (optional step)

Week 21+ → 15.0 mg (maintenance)

Source: FDA Label (Mounjaro/Zepbound)

The SURMOUNT-1 trial showed tirzepatide at the maximum dose achieved 22.5% mean weight loss over 72 weeks — the largest weight reduction seen in a Phase III obesity trial at the time of publication.

5. Retatrutide: The Triple Agonist

Retatrutide (LY3437943) is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor activation adds thermogenesis (increased energy expenditure) on top of the appetite suppression and insulin secretion provided by GLP-1/GIP agonism. Half-life: ~6 days.

Retatrutide Phase II Schedule

Weeks 1-4 → 1.0 mg

Weeks 5-8 → 2.0 mg

Weeks 9-12 → 4.0 mg

Weeks 13-16 → 8.0 mg

Week 17+ → 12.0 mg (maintenance)

Source: PMID: 37351564 (Phase II)

Phase II results showed up to 24.2% mean weight loss at the 12 mg dose over 48 weeks. Retatrutide is currently in Phase III trials (TRIUMPH program) with expected results in 2025-2026.

6. Reconstituting Compounded GLP-1 Peptides

Compounded semaglutide and tirzepatide typically come as lyophilized powder in vials of 3 mg, 5 mg, or 10 mg. Unlike brand-name auto-injectors (which are pre-mixed), compounded versions require reconstitution with bacteriostatic water.

The reconstitution math is identical to any other peptide — concentration equals vial size divided by water volume. Use our Reconstitution Calculator for instant results.

Vial	Water	Conc.	0.25 mg dose	1.0 mg dose	2.4 mg dose
5 mg	2 mL	2.5 mg/mL	10 units	40 units	96 units
5 mg	1 mL	5 mg/mL	5 units	20 units	48 units
3 mg	1 mL	3 mg/mL	8.3 units	33.3 units	80 units
10 mg	2 mL	5 mg/mL	5 units	20 units	48 units

7. Calculating Syringe Units for Each Dose Step

Units = Dose (mg) ÷ Concentration (mg/mL) × 100

Example for Wegovy schedule with 5 mg / 2 mL reconstitution (2.5 mg/mL):

Phase	Dose	Calculation	Draw	Syringe
Month 1	0.25 mg	0.25 ÷ 2.5 × 100	10 units	30u syringe
Month 2	0.5 mg	0.5 ÷ 2.5 × 100	20 units	30u syringe
Month 3	1.0 mg	1.0 ÷ 2.5 × 100	40 units	50u syringe
Month 4	1.7 mg	1.7 ÷ 2.5 × 100	68 units	100u syringe
Maintenance	2.4 mg	2.4 ÷ 2.5 × 100	96 units	100u syringe

8. Managing Side Effects During Escalation

The most common side effects of GLP-1 agonists are gastrointestinal. They typically peak during the first 1-2 weeks of each new dose level and diminish with continued use.

Nausea

Eat smaller meals, avoid greasy/spicy food, stay hydrated. Usually resolves within 1-2 weeks.

Constipation

Increase fiber intake, drink more water, consider osmotic laxatives (PEG 3350).

Injection site reactions

Rotate injection sites between abdomen, thigh, and upper arm. Apply ice before injection.

Fatigue

Common during first week of escalation. Ensure adequate protein intake (≥1 g/kg) and hydration.

9. Half-Life Comparison Table

Peptide	Half-Life	Type	Max Dose
Semaglutide	~7 days	GLP-1 mono	2.4 mg/week
Tirzepatide	~5 days	GIP/GLP-1 dual	15 mg/week
Retatrutide	~6 days	GIP/GLP-1/GCG triple	12 mg/week
Liraglutide	~13 hours	GLP-1 mono	3.0 mg/day
Exenatide ER	~2 hours (ER: days)	GLP-1 mono	2 mg/week

10. Clinical Weight Loss Data

Trial	Drug	Dose	Duration	Weight Loss
STEP 1	Semaglutide	2.4 mg/wk	68 weeks	-14.9%
SURMOUNT-1	Tirzepatide	15 mg/wk	72 weeks	-22.5%
Phase II	Retatrutide	12 mg/wk	48 weeks	-24.2%
SCALE	Liraglutide	3.0 mg/day	56 weeks	-8.0%

All values are mean placebo-adjusted body weight reduction. Sources: PMID: 33567185, PMID: 35658024, PMID: 37351564.

11. Frequently Asked Questions

Can I skip dose escalation steps?

Not recommended. Skipping steps significantly increases the risk of severe nausea, vomiting, and other GI side effects. The escalation schedule exists because clinical trials found it necessary for tolerability.

What if I miss a dose during escalation?

If fewer than 5 days have passed (semaglutide), take the missed dose immediately. If more than 5 days have passed, skip it and continue on your regular schedule. Do not double-dose.

Is semaglutide or tirzepatide more effective?

Head-to-head data from the SURPASS clinical program suggests tirzepatide achieves greater weight loss (~22.5% vs ~14.9%). However, individual responses vary and the best choice depends on a patient's medical history and tolerability.

Can I use the same vial across escalation steps?

Yes — with compounded peptides, you can use the same reconstituted vial and simply adjust the number of syringe units drawn for each dose step. However, the vial must be used within 28 days of reconstitution.

When will retatrutide be FDA-approved?

Retatrutide is in Phase III clinical trials (TRIUMPH program). If results are positive, FDA filing is expected in late 2025/2026 with potential approval in 2026/2027.

Generate Your Personal Schedule

Enter your start date and medication to get a week-by-week escalation plan with syringe units.

Open GLP-1 Scheduler

Medical disclaimer: This guide is for educational purposes only. Consult a licensed healthcare provider before starting any GLP-1 agonist. Contact us at contact@calcmypeptide.com.